Tekcapital plc Strategy/Company/Ops Update (4089C)
10 February 2020 - 6:00PM
UK Regulatory
TIDMTEK
RNS Number : 4089C
Tekcapital plc
10 February 2020
The information contained within this announcement is deemed by
the Company to constitute inside information as stipulated under
the Market Abuse Regulations (EU) No. 596/2014 ("MAR"). With the
publication of this announcement via a Regulatory Information
Service ("RIS"), this inside information is now considered to be in
the public domain.
10 February 2020
Tekcapital plc
("Tekcapital" or the "Company")
Portfolio Company Update
Belluscura plc files new patent application for devices and
systems for treating people
suffering from acute respiratory distress caused by the
Coronavirus
Tekcapital plc, (AIM: TEK) the UK intellectual property
investment group focused on creating marketplace value from
investing in university technology, announces that its portfolio
company Belluscura plc has recently filed a patent application on
an oxygen enrichment device and system for treating acute
respiratory distress (ARDS), including ARDS caused by
Coronavirus.
Belluscura plc, in conjunction with its exclusive research
partner Separation Design Group, announced the filing of a patent
application covering novel integrated portable extracorporeal
oxygenation and carbon dioxide removal systems for treating
patients suffering from ARDS.
The latest patent application covers devices and systems for
treating people suffering from ARDS including patients suffering
from the coronavirus. The primary cause of death from respiratory
viruses like the coronavirus and influenza, are the result of the
fluids accumulating inside the alveoli (the tiny air sacs of the
lungs) which ultimately leads to the failure of the transfer of
oxygen to and carbon dioxide out of the blood. The current primary
treatment for ARDS is oxygen therapy along with ventilator
support.
In cases where oxygen therapy and ventilator support are not
effective, extracorporeal membrane oxygenation (ECMO), which
circulates a patient's blood through an oxygenation membrane, has
been used to remove carbon dioxide from and diffuse oxygen into a
patient's blood while giving a patient's lungs a chance to recover.
Belluscura and Separation Design are designing and developing next
generation, cost-effective, portable ECMO technology to treat ARDS
patients.
Commenting on the patenting activities, Bob Rauker, CEO of
Belluscura, said: "We are very excited about our next generation
oxygen technologies. With the launch this year of our first
product, the X-PLOR(TM) portable oxygen concentrator, into the
respiratory treatment field where over 250 million people suffer
from chronic obstructive pulmonary disease (COPD), the third
leading cause of death, it is critical that we continue to innovate
into the ever-expanding oxygen therapy market."
About Belluscura plc
Belluscura is focused on developing novel oxygen-based treatment
platforms that can be adapted and applied in a wide range of
markets beyond those traditionally applicable to a single product
or product line. Belluscura is developing innovative enriched
oxygen treatment platforms that reduce the cost of treatment and
increase available treatment options. To learn more about
Belluscura, please visit www.belluscura.com.
Tekcapital owns 18.9% of the share capital of Belluscura.
Clifford M. Gross Ph.D., Executive Chairman of Tekcapital plc
commented:
"We are pleased to see the additional progress of Belluscura as
it continues to strengthen its intellectual property in the oxygen
therapy space to help patients afflicted with acute respiratory
distress caused by the Coronavirus. Additionally, we anticipate
that Belluscura is likely to receive FDA clearance for their
portable oxygen concentrator within the next 90 days. "
About Tekcapital plc
Tekcapital creates value from investing in new,
university-developed intellectual properties and provides a range
of IP investment services to make it easy for organisations to
commercialise university-developed technology. Tekcapital is quoted
on the AIM market of the London Stock Exchange (AIM: symbol TEK)
and is headquartered in Oxford, in the UK. For more information,
please visit www.tekcapital.com.
LEI: 213800GOJTOV19FIFZ85
For further information, please contact:
Tekcapital Plc Via Flagstaff
Clifford M. Gross, Ph.D.
SP Angel Corporate Finance LLP (Nominated
Adviser and Joint Broker) +44 (0) 20 3470 0470
Richard Morrison/Charlie Bouverat (Corporate
Finance)
Abigail Wayne (Corporate Broking)
Novum Securities Limited (Joint Broker) +44 (0) 20 7399 9427
Colin Rowbury (Corporate Broking)
Flagstaff Strategic and Investor Communications +44 (0) 20 7129 1474
Tim Thompson/Andrea Seymour/Fergus Mellon
This press release is for informational purposes only. The
information herein does not constitute investment advice nor an
offer to invest and may contain statements related to our future
business and financial performance and future events or
developments involving Tekcapital or Belluscura that may constitute
forward-looking statements. These statements may be identified by
words such as "expect," "look forward to," "anticipate" "intend,"
"plan," "believe," "seek," "estimate," "will," "project" or words
of similar meaning. We may also make forward-looking statements in
other reports, in presentations, in material delivered to
customers, stakeholders and in press releases. In addition, our
representatives may from time to time make oral forward-looking
statements. Such statements may be based on the current
expectations and certain assumptions of Tekcapital or Belluscura's
management. Please note that these are subject to a number of
risks, uncertainties and factors, including, but not limited to
those described in various disclosures. Should one or more of these
risks or uncertainties materialize, or should underlying
expectations not occur or assumptions prove incorrect, actual
results, performance or achievements of Salarius may vary
materially from those described explicitly or implicitly in the
relevant forward-looking statement. Neither Tekcapital nor
Belluscura intends, nor assumes any obligation, to update or revise
these forward-looking statements in light of developments which
differ from those anticipated.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
UPDUWRARRBUURAR
(END) Dow Jones Newswires
February 10, 2020 02:00 ET (07:00 GMT)
Tekcapital (LSE:TEK)
Historical Stock Chart
From Apr 2024 to May 2024
Tekcapital (LSE:TEK)
Historical Stock Chart
From May 2023 to May 2024